New pill aims to stop stomach bug in its tracks
NCT ID NCT07198139
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental oral drug called CDI-988 in 40 healthy adults aged 18 to 49. Participants receive either the drug or a placebo before being exposed to norovirus, the highly contagious stomach bug. The goal is to see if CDI-988 reduces vomiting and diarrhea compared to placebo, and to check for side effects. The study is still recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NOROVIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hope Clinic of the Emory Vaccine Center
RECRUITINGDecatur, Georgia, 30030, United States